Skip to main content
Premium Trial:

Request an Annual Quote

Back to the Supreme

The gene patenting fight is heading back to the US Supreme Court, the Associated Press reports. According to ScienceInsider, the court added that it will only consider the issue of whether human genes are "patent-eligible."

"It will be very useful to get a definitive ruling on some of the issues at stake," Hank Greely, a Stanford University law professor tells the Nature News Blog.

As Daily Scan's sister publication GenomeWeb Daily News notes, the case was first filed in 2009 by the American Civil Liberties Union, the Public Patent Foundation, the Association for Molecular Pathology, and others against Myriad Genetics concerning its patents surrounding the BRCA1 and BRCA2 genes. The suit has since been wending its way through the legal system. The Court of Appeals for the Federal Circuit ruled recently, after being directed by the Supreme Court to reconsider the case, that isolated DNA is patentable.

The AP adds that the case will likely go before the Supreme Court in the spring, with its ruling to follow in the summer.

The Scan

Rare Genetic Disease Partnership

A public-private partnership plans to speed the development of gene therapies for rare genetic diseases, Stat News writes.

Approval Sought for Alzheimer's Drug

The Wall Street Journal reports Eli Lilly has initiated a rolling submission to the US Food and Drug Administration to seek approval for its drug to treat Alzheimer's disease.

DNA Barcoding Paper Retracted

Science reports that a 2014 DNA barcoding paper was retracted after a co-author brought up data validity concerns.

Nature Papers Present Genomic Analysis of Bronze Age Mummies, Approach to Study Host-Pathogen Interactions

In Nature this week: analysis finds Tarim mummies had local genetic origin, and more.